Takeda Expands Presence in India with Launch of Global Innovation Capability Center in Bengaluru

Takeda Innovation Capability Center to Fill Upwards of 750 Roles, Strengthening Bengaluru's Global Innovation Landscape

BENGALURU, India, January 15, 2025, - Takeda (TSE:4502/NYSE:TAK), a global leader in biopharmaceutical innovation, today announced the official opening of its Innovation Capability Center (ICC) in Bengaluru, India, a center where digital solutions will be built as part of Takeda’s global digital transformation, which includes insourcing capabilities. This marks Takeda’s first ICC in Asia, following successful establishments in Slovakia and Mexico. The ICC help support the company’s dedication to advancing healthcare through innovative solutions. These cutting-edge solutions will help advance our operations and have an impact on Takeda’s workforce, the patients that we serve and the planet for years to come.

The launch of ICC India represents Takeda’s strategic commitment to apply data and new digital technologies, such as artificial intelligence, having the potential to accelerate research and development with the ultimate goal of transforming the lives of patients. Takeda is focused on creating better health for people and a brighter future for the world, with a steadfast commitment to its core values: Integrity, Fairness, Honesty and Perseverance. With a rich history that dates back to 1781 in Osaka, Japan, Takeda has grown into a global biopharmaceutical leader, operating in approximately 80 countries, including in India for more than 13 years. The company’s mission in India focuses on ensuring sustainable access to health care, bolstered by strategic partnerships. Takeda’s diverse therapeutic portfolio addresses gastrointestinal disorders, rare diseases, immunology, oncology and vaccines, underscoring its commitment to data-driven innovation and transforming treatments.

The establishment of this capability center underlines Takeda’s ambition to transform into one of the most trusted, values-based, R&D-driven biopharmaceutical companies, tapping into Karnataka’s vibrant ecosystem of innovation to serve patient needs.

“The launch of our Bengaluru ICC is a pivotal moment for Takeda’s digital transformation journey,” said Gabriele Ricci, Chief Data and Technology Officer at Takeda. “Tapping into local talent is vital in our quest to create better health for people and a brighter future for the communities we serve. Investing in India’s remarkable talent and technological expertise underscores Takeda’s commitment leveraging local expertise to deliver innovative, data-driven solutions and sustainable growth.”

The ICC in India will develop key technology capabilities to fuel innovation by embracing data and digital solutions using an agile, patient-centric and solution focused approach. The ICC will concentrate on pioneering advancements across domains including:

• Artificial Intelligence (AI) and GenAI to enhance efficiency and predictive analytics in healthcare
• Device Engineering and Application Virtualization to drive innovation in product development and patient-centric solutions
• Data Science and Visualization to enable data-driven decision-making for improved patient outcomes

“India was a natural choice for Takeda’s first ICC in Asia,” said Tilak Banerjee, Head of Takeda ICC India. “This strategic commitment will generate new jobs and further the company’s global mission of delivering life-transforming treatments to patients.”